Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ARPIs Beneficial in Prostate Cancer
TOPLINE: In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months vs the 6.9 months seen with taxanes. Overall survival was also higher for those taking ARPIs…
English